Physician profile
Ian Baxter
NPI 1902890148
$156,821.51
in general payments reported to CMS, 2019-2025
21 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $6,172 · 2021: $24K · 2022: $37K · 2023: $16K · 2024: $12K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $28K · Consulting Fee: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,816 · Travel and Lodging: $1,796 · Food and Beverage: $1,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $27,872.32 |
| Consulting Fee | $10,382.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,816.00 |
| Travel and Lodging | $1,796.42 |
| Food and Beverage | $1,415.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $69,898.86 | 2021-2025 | Nexplanon, Nuvaring |
| Merck Sharp & Dohme LLC | $38,579.42 | 2019-2025 | Gardasil, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $28,320.83 | 2019-2025 | |
| Biogen, INC. | $9,800.31 | 2025 | Zurzuvae |
| Lupin INC. | $8,788.11 | 2019 | |
| Evofem Biosciences, INC. | $261.01 | 2022-2025 | Phexxi, Solosec, Phexx |
| Myovant Sciences INC. | $213.87 | 2022 | |
| Sumitomo Pharma America, INC. | $170.24 | 2023-2025 | Myfembree, Gemtesa |
| Sage Therapeutics, LLC | $160.36 | 2022-2025 | Zurzuvae |
| Abbvie INC. | $150.93 | 2022-2025 | Orilissa, Liletta |
| Astellas Pharma US INC | $145.55 | 2023-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $81.63 | 2023-2025 | Slynd |
| Boston Scientific Corporation | $66.41 | 2025 | Spaceoar System |
| Baxter Healthcare | $41.25 | 2024 | Floseal |
| Pfizer INC. | $31.07 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $27.34 | 2024 | Bd Max System, Bd Max Instrument |
| Shield Therapeutics INC | $22.24 | 2024 | |
| Shire North American Group INC | $20.04 | 2019 | |
| Mallinckrodt Enterprises LLC | $16.90 | 2019 | |
| Hologic Sales and Service, LLC | $13.50 | 2022 | |
| Allergan, INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.